EHA 2023 | Bispecifics & CARs: BCMA, GPRC5D & FcRH5 sequencing
Susan Bal
• 10 Jun 2023
The introduction of agents targeting BCMA has revolutionized the myeloma space. With modalities targeting GPRC5D and FcRH5 successfully making their way through pharmaceutical pipelines, the question of sequencing arises. In this video, Susan Bal, MD, MBBS, University of Alabama at Birmingham, Birmingham, AL, discusses how these agents may be packaged together in an algorithm. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
